Menu ×

HEALTHCARE & PHARMACEUTICAL

Prostaglandin Market Segmentation by Type (Human, and Veterinary Prostaglandin); by Application (Cardiology, Gastroenterology, Ophthalmology, Gynecology & Obstetrics, and Others) – Global Demand Analysis & Opportunity Outlook 2029

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More

Global Prostaglandin Market Highlights 2020-2029

The global prostaglandin market is anticipated to record a moderate CAGR over the forecast period, i.e., 2021-2029. The market is primarily driven by the increasing complications observed among women during labor in the process of childbirth, along with the increasing use of prostaglandins in obstetric practices.

Introduction to Prostaglandins

Prostaglandins are hormone-like compounds that are derived enzymatically in the human body from arachidonic acid (a type of fatty acid). The primary function of prostaglandin in humans is to create eicosanoids hormones, induce fever by acting on the thermoregulatory center of the hypothalamus, and initiate labor in pregnancy. During the process of childbirth, prostaglandin helps to contract the muscles of the uterine walls, which helps to push the baby out of the uterus. The suppositories of prostaglandin are inserted into the vagina in the evening which helps the mother go into labor by the next morning. Further, when the human or animal body is bleeding, prostaglandins stimulate the formation of blood clots and contraction of blood vessels. Apart from the use of prostaglandins in the reproductive area, it is widely distributed in the human body to produce different pharmacological effects, such as regulation of blood pressure, treatment of hypertension, and peripheral vascular disease among others. These compounds are also used clinically for induction of labor and to reduce early pregnancies. Primarily, there are four different types of prostaglandin, namely, prostaglandin I2 (PGI2), prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), and prostaglandin F2 alpha (PGF2∞), the comparison of which is given below:

Different-Types-of-Prostaglandins

Get more information on this report: Download Sample PDF

Market Size and Forecast

The global prostaglandin market is further thriving on account of the numerous properties associated with the compound, which makes it widely accepted in different health applications, including cardiology, gastroenterology, ophthalmology, gynecology & obstetrics, and others. Also, the role of prostaglandins in the pathophysiology and treatment of various vascular disorders by the utilization of the compound is further expected to boost the market growth in the near future. The market is segmented on the basis of application into cardiology, gastroenterology, ophthalmology, gynecology & obstetrics, and others, out of which, the cardiology segment is projected to account for the leading market share in the year 2021 on the back of an increasing number of geriatric populations across the globe and the growing incidences of cardiovascular diseases worldwide. According to the statistics by the World Health Organization (WHO), the proportion of the global population aged 60 years and above is projected to double from 12% to 22% between 2015 and 2050. Alternatively, the gynecology & obstetrics segment is projected to grow with the highest CAGR during the forecast period on account of the increasing applications of human prostaglandin medications in women during pregnancy. Further, the growing utilization of prostaglandin synthetase inhibitors, such as ibuprofen, indomethacin, ibuprofen and mefenamic acid for the treatment of primary dysmenorrhea, is also anticipated to help drive the growth of the segment during the forecast period. 

/Global-Prostaglandin-Market-Share

Growth Drivers

Increasing Application of Prostaglandin for Treating Patients Suffering from Migraine Headaches

Migraine is a neurological condition that is frequently characterized by debilitating and intense headaches. Some of the major symptoms caused by migraines include vomiting, sensitivity to light & sound, nausea, and others. One of the major reasons for implicating prostaglandins in pathogenesis is for the cause of migraine headaches. These compounds are able to constrict or relax the cerebral blood vessels, which helps in reducing migraine headaches. Moreover, these compounds have reportedly known to potentiate the effects of bradykinin and other forms of chemically induced pain by sensitizing the peripheral pain receptors. Additionally, prostaglandin also helps in the diagnosis of inflammatory diseases, such as edema, erythema, and tissue damage, and is capable of modulating the release of neurotransmitters from nerve terminals. Prostaglandin inhibitors are also effectively used for shortening the duration of migraine attacks and reduce the side effects such as nausea, vomiting, and abdominal pain.

Increase in the Number of Cardiovascular Patients

In other statistics by the WHO, every year 17.9 million people die due to cardiovascular diseases.

Development in the area of neonatal cardiac surgery has increased the importance of rapid diagnosis and stabilization of infants with congenital heart disease. With the increasing applications of prostaglandin in the early stages of detection of cardiovascular diseases, the compound helps the patients to be more clinically stable for surgery. Therapy with prostaglandin can effectively maintain an infant's cardiovascular function until a palliative or corrective procedure can be performed. Additionally, the growing geriatric population with major congenital heart disease is further projected to enhance the market growth over the forecast period.

Restraints

Health Concerns Associated with the Uneven Production of Prostaglandins

The primary issues with uneven prostaglandins are the unwanted inflammation in the body. Excessive production of prostaglandin can cause chronic diseases with significant pain. Moreover, menstruation bleeding, arthritis, and some types of cancer, among others are connected to the high amount of prostaglandin formation. Sometimes, the formation of prostaglandin is not enough to heal the injury, which in turn is also anticipated to hamper the market growth over the forecast period.

Market Segmentation

Our in-depth analysis of the global prostaglandin market includes the following segments:

By Type

  • Human Prostaglandin
  • Veterinary Prostaglandin

By Application

  • Cardiology
  • Gastroenterology
  • Ophthalmology
  • Gynecology & Obstetrics
  • Others

By Region

On the basis of regional analysis, the global prostaglandin market is segmented into five major regions including North America, Europe, Asia Pacific and the Middle East & Africa region. Among these regions, the market in North America is expected to display significant growth owing to the increasing number of patients having congenital heart diseases. According to the statistics by the Centers for Disease Control and Prevention (CDC), about 655,000 Americans die from heart disease each year. Moreover, the presence of a strong healthcare network in the region, along with increasing investments by the pharmaceutical companies for the research and development of advanced hormone-like compounds are some of the additional factors anticipated to drive the market growth in North America.

The global prostaglandin market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved